Caladrius Biosciences Stock Price, News & Analysis (NASDAQ:CLBS)

$3.50 -0.08 (-2.23 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$3.58
Today's Range$3.48 - $3.58
52-Week Range$2.63 - $7.79
Volume34,600 shs
Average Volume59,924 shs
Market Capitalization$33.91 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio5.78%
Quick Ratio5.78%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.28 million
Price / Sales0.94
Cash FlowN/A
Price / CashN/A
Book Value$0.50 per share
Price / Book7.00

Profitability

Trailing EPS$2.11
Net Income$-32,650,000.00
Net Margins-84.10%
Return on Equity-96.80%
Return on Assets-43.98%

Miscellaneous

Employees209
Outstanding Shares9,470,000

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences Inc (NASDAQ:CLBS) released its quarterly earnings data on Thursday, November, 9th. The biotechnology company reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.79) by $0.41. Caladrius Biosciences had a negative net margin of 84.10% and a negative return on equity of 96.80%. View Caladrius Biosciences' Earnings History.

Where is Caladrius Biosciences' stock going? Where will Caladrius Biosciences' stock price be in 2017?

1 brokers have issued 12-month price objectives for Caladrius Biosciences' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate Caladrius Biosciences' stock price to reach $7.00 in the next twelve months. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:

  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 73)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

How do I buy Caladrius Biosciences stock?

Shares of Caladrius Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of Caladrius Biosciences stock can currently be purchased for approximately $3.50.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $33.91 million and generates $35.28 million in revenue each year. The biotechnology company earns $-32,650,000.00 in net income (profit) each year or $2.11 on an earnings per share basis. Caladrius Biosciences employs 209 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (CLBS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  179 (Vote Outperform)
Underperform Votes:  114 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Caladrius Biosciences (NASDAQ:CLBS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.672.752.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.75$6.75$6.75$4.88
Price Target Upside: 115.65% upside115.65% upside72.19% upside4.97% downside

Caladrius Biosciences (NASDAQ:CLBS) Consensus Price Target History

Price Target History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017HC WainwrightReiterated RatingBuy$7.00N/AView Rating Details
11/9/2016Chardan CapitalReiterated RatingBuy$6.50N/AView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
1/26/2016AegisReiterated RatingBuyN/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Caladrius Biosciences (NASDAQ:CLBS) Earnings History and Estimates Chart

Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.79)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.12)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Caladrius Biosciences (NASDAQ:CLBS) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.33 EPS
Next Year EPS Consensus Estimate: $-2.94 EPS

Dividends

Dividend History for Caladrius Biosciences (NASDAQ:CLBS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Caladrius Biosciences (NASDAQ CLBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 6.41%
Insider Trades by Quarter for Caladrius Biosciences (NASDAQ:CLBS)
Institutional Ownership by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Caladrius Biosciences (NASDAQ CLBS) News Headlines

Source:
DateHeadline
Caladrius Biosciences (CLBS) versus Its Peers Head to Head ReviewCaladrius Biosciences (CLBS) versus Its Peers Head to Head Review
www.americanbankingnews.com - December 12 at 9:34 PM
ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:14 PM
Caladrius Biosciences (CLBS) vs. Its Competitors Financial ReviewCaladrius Biosciences (CLBS) vs. Its Competitors Financial Review
www.americanbankingnews.com - December 4 at 1:34 AM
Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)
globenewswire.com - December 3 at 5:20 PM
Zacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to HoldZacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to Hold
www.americanbankingnews.com - November 16 at 5:34 PM
Caladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
Caladrius Biosciences, Inc. (CLBS) Releases  Earnings Results, Beats Expectations By $0.41 EPSCaladrius Biosciences, Inc. (CLBS) Releases Earnings Results, Beats Expectations By $0.41 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Caladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC WainwrightCaladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)
www.globenewswire.com - November 10 at 9:52 AM
What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?What Is Caladrius Biosciences Inc’s (CLBS) Share Price Doing?
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences, Inc. to Host Earnings CallCaladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences Reports 2017 Third Quarter ResultsCaladrius Biosciences Reports 2017 Third Quarter Results
finance.yahoo.com - November 9 at 8:12 PM
Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)Caladrius Biosciences to Participate at Upcoming November Conferences - GlobeNewswire (press release)
globenewswire.com - November 2 at 6:08 PM
Caladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Third Quarter Business Update Conference Call on November 9, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - November 2 at 6:08 PM
Caladrius Biosciences to Participate at Upcoming November ConferencesCaladrius Biosciences to Participate at Upcoming November Conferences
finance.yahoo.com - November 1 at 6:02 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
Caladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 11 at 5:56 PM
Caladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head ReviewCaladrius Biosciences (CLBS) and Global Blood Therapeutics (GBT) Head-To-Head Review
www.americanbankingnews.com - October 11 at 12:08 AM
Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)Head-To-Head Survey: Caladrius Biosciences (CLBS) and Enanta Pharmaceuticals (ENTA)
www.americanbankingnews.com - October 6 at 4:28 AM
How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?How Long Will Loss-Making Caladrius Biosciences Inc (CLBS) Survive?
finance.yahoo.com - October 5 at 11:22 AM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMDCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD
www.streetinsider.com - October 4 at 12:08 PM
Caladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.comCaladrius Biosciences (CLBS) Announces $2M NIH Grant to Support Clinical Study of CLBS14 in Patients with CMD - StreetInsider.com
www.streetinsider.com - October 2 at 10:26 PM
Caladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular DysfunctionCaladrius Biosciences Awarded Approximately $2 Million NIH Grant to Support Clinical Study of CLBS14 in Patients with Coronary Microvascular Dysfunction
finance.yahoo.com - October 2 at 5:25 PM
Caladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the MesaCaladrius Biosciences to Participate at the 2017 Cell & Gene Meeting on the Mesa
globenewswire.com - September 28 at 8:42 AM
Why These 4 Biotech Stocks May Not Lose Momentum Soon - NasdaqWhy These 4 Biotech Stocks May Not Lose Momentum Soon - Nasdaq
www.nasdaq.com - September 11 at 5:55 PM
Why These 4 Biotech Stocks May Not Lose Momentum SoonWhy These 4 Biotech Stocks May Not Lose Momentum Soon
finance.yahoo.com - September 11 at 5:55 PM
Type 1 Diabetes May Soon Meet Its MatchType 1 Diabetes May Soon Meet Its Match
finance.yahoo.com - September 8 at 5:40 PM
Caladrius Biosciences to Participate at Upcoming September Conferences - NasdaqCaladrius Biosciences to Participate at Upcoming September Conferences - Nasdaq
www.nasdaq.com - September 8 at 3:21 AM
Caladrius Biosciences to Participate at Upcoming September ConferencesCaladrius Biosciences to Participate at Upcoming September Conferences
finance.yahoo.com - September 7 at 5:19 PM
Caladrius Biosciences (CLBS) "Buy" Rating Reiterated at HC WainwrightCaladrius Biosciences' (CLBS) "Buy" Rating Reiterated at HC Wainwright
www.americanbankingnews.com - September 6 at 3:56 PM
Caladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.comCaladrius Biosciences (CLBS) Reports Enrollment of 70th Subject in Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 ... - StreetInsider.com
www.streetinsider.com - September 5 at 6:47 PM
Caladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Announces Enrollment of the 70th Subject in the Phase 2 T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - September 5 at 6:47 PM
Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)Critical Analysis: Arbutus Biopharma Corp (ABUS) and Caladrius Biosciences (CLBS)
www.americanbankingnews.com - August 25 at 6:28 AM
Caladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC WainwrightCaladrius Biosciences, Inc. (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - August 13 at 3:32 PM
Caladrius Biosciences, Inc. (CLBS) Posts  Earnings Results, Beats Estimates By $0.08 EPSCaladrius Biosciences, Inc. (CLBS) Posts Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - August 11 at 12:24 PM
Investor Network: Caladrius Biosciences, Inc. to Host Earnings CallInvestor Network: Caladrius Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences Reports 2017 Second Quarter ResultsCaladrius Biosciences Reports 2017 Second Quarter Results
finance.yahoo.com - August 10 at 6:29 PM
Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)Caladrius Biosciences to Host 2017 Second Quarter Results ... - GlobeNewswire (press release)
globenewswire.com - August 3 at 11:50 PM
Caladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host 2017 Second Quarter Results Conference Call on August 10, 2017 at 4:30 p.m. Eastern Time
finance.yahoo.com - August 3 at 6:48 PM
Caladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on MondayCaladrius Biosciences, Inc. (CLBS) Set to Announce Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) Receives "Buy" Rating from HC WainwrightCaladrius Biosciences, Inc. (NASDAQ:CLBS) Receives "Buy" Rating from HC Wainwright
www.americanbankingnews.com - July 21 at 7:50 AM
Caladrius Biosciences (CLBS) Says 50% of Subjects Have Been ... - StreetInsider.comCaladrius Biosciences (CLBS) Says 50% of Subjects Have Been ... - StreetInsider.com
www.streetinsider.com - July 19 at 11:29 PM
Caladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Announces that 50% of Subjects Have Been Treated in the Phase 2 Clinical Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - July 19 at 6:23 PM
ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017ETFs with exposure to Caladrius Biosciences, Inc. : July 12, 2017
finance.yahoo.com - July 12 at 5:53 PM
-$0.96 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter-$0.96 Earnings Per Share Expected for Caladrius Biosciences, Inc. (NASDAQ:CLBS) This Quarter
www.americanbankingnews.com - July 4 at 10:28 PM
Caladrius Biosciences Joins Russell Microcap® Index - NasdaqCaladrius Biosciences Joins Russell Microcap® Index - Nasdaq
www.nasdaq.com - June 26 at 5:00 PM
Caladrius Biosciences (CLBS) Presents At 7th Annual LD Micro Invitational Conference - SlideshowCaladrius Biosciences (CLBS) Presents At 7th Annual LD Micro Invitational Conference - Slideshow
seekingalpha.com - June 7 at 7:09 PM
Caladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)Caladrius Biosciences Announces 2017 First Quarter Financial Results - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:38 AM
Caladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)Caladrius Biosciences to Participate at Upcoming May Conferences - GlobeNewswire (press release)
globenewswire.com - May 1 at 8:39 AM
The Strange Case Of Caladrius Biosciences - Seeking AlphaThe Strange Case Of Caladrius Biosciences - Seeking Alpha
seekingalpha.com - April 19 at 9:21 PM

SEC Filings

Caladrius Biosciences (NASDAQ:CLBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Caladrius Biosciences (NASDAQ:CLBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Caladrius Biosciences (NASDAQ CLBS) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.